Extended persistence of antiphospholipid antibodies beyond the 12-week time interval: Association with baseline antiphospholipid antibodies titres.
anticardiolipin antibodies
antiphospholipid antibodies
antiphospholipid syndrome
lupus anticoagulant
Journal
International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
21
03
2019
revised:
14
06
2019
accepted:
22
07
2019
pubmed:
17
9
2019
medline:
3
4
2020
entrez:
17
9
2019
Statut:
ppublish
Résumé
The confirmation time interval for the presence of antiphospholipid antibodies (aPL) has been extended to 12 weeks as epiphenomenal antibodies may disappear after 6 weeks. Our aim was to analyse extended persistence of aPL positivity beyond the 12-week interval. We retrospectively analysed our database of 23 856 aPL test samples collected between 2005 and 2017 from 17 367 consecutive patients. Two groups of patients were identified among aPL-positive patients, confirmed at 12 weeks: with or without extended persistence beyond confirmatory testing. Percentages of extended persistence are given according to the initial aPL positivity profiles, and baseline laboratory variables are compared between the two groups. Three hundred and twenty-seven patients confirmed aPL-positive had subsequent testing. The vast majority of them displayed extended persistence in the long term: 89.6% and up to 97.9% for patients with initial triple positivity. In extended persistent positive patients, there were more LA-positive initial samples, and baseline LA test values and IgG aCL titres were higher than in nonpersistent positive patients. Data from a large database of an aPL referral laboratory showed that the time interval of 12 weeks defining persistence of aPL positivity was appropriate for the majority of patients. Furthermore, we found baseline features associated with extended persistence.
Substances chimiques
Antibodies, Antiphospholipid
0
Lupus Coagulation Inhibitor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
726-730Subventions
Organisme : Association des Chefs de Service
Organisme : Contrat de Plan Etat-Region
ID : IT2MP
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309-1311.
Abdel-Wahab N, Lopez-Olivo MA, Pinto-Patarroyo GP, Suarez-Almazor ME. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus. 2016;25:1520-1531.
Park SH, Jang S, Park C-J, Chi H-S. Clinical application of revised laboratory classification criteria for antiphospholipid antibody syndrome: is the follow-up interval of 12 weeks instead of 6 weeks significantly useful? Biomed Res Int. 2016;2016:2641526.
Solano C, Lamuño M, Vargas A, Amezcua-Guerra LM. Comparison of the 1999 Sapporo and 2006 revised criteria for the classification of the antiphospholipid syndrome. Clin Exp Rheumatol. 2009;27:914-919.
Pengo V, Ruffatti A, Del Ross T, et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost. 2013;11:1527-1531.
Pengo V, Denas G. Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): a personal perspective. Thromb Res. 2018;169:35-40.
Pengo V, Tripodi A, Reber G, et al. Groot PG. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2009;7:1737-1740.
Lakos G, Favaloro EJ, Harris EN, et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th international congress on antiphospholipid antibodies. Arthritis Rheum. 2012;64:1-10.
Wahl D, Devignes J, Mohamed S, Zuily S, Lecompte T. Definition and significance of high positivity aCL ELISA. Lupus. 2012;21:725-726.